Investigating the Clinical Consequences of Flutemetamol-PET-scanning

Inclusion Criteria

• •Dementia expert considers an Amyloid-scan appropriate according to Amyloid-imaging task force criteria (AIT) after conference with an Amyloid-PET expert
• •Preambles of the AIT-Criteria are fulfilled
• •1. A cognitive complaint with objectively confirmed impairment
• •2. AD as a possible diagnosis, but when the diagnosis is uncertain after a comprehensive evaluation by a dementia expert
• •3. When knowledge of the presence or absence of Abeta pathology is expected to increase diagnostic certainty and alter Management
• •<!-- -->
• •1. Patients with persistent or progressive unexplained MCI
• •2. Patients satisfying core clinical criteria for possible AD because of unclear clinical presentation, either an atypical clinical course or an etiologically mixed presentation
• •3. Patients with progressive dementia and atypically early age of onset (65 years or less in age)
• •4. other situations where preambles of AIT-Criteria are fulfilled
• •Diagnosis was established in a memory clinic or by an experienced physician in dementia diagnostics
• •The diagnostic procedures comprise in minimum MRI, neuropsychology, routine blood test for exclusion of symptomatic causes
• •MMSE \>15
• •Competency to consent
• •Trial partner willing to support study physician
• •Written informed consent by both patient and trial partner
• •Understanding of German language
• •Treating physician willing to collaborate with the study team